The Technical Analyst
Applied Therapeutics Inc [APLT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Applied Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
1.18% $4.28
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 488.96 mill |
| EPS: | -1.420 |
| P/E: | -3.01 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 114.24 mill |
| Avg Daily Volume: | 1.810 mill |
| RATING 2024-04-26 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.01 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.51x |
| Company: PE -3.01 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.174 (-72.56%) $-3.11 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.73 - 4.84 ( +/- 12.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-12 | Hooks Corwin Dale | Buy | 300 000 | Common Stock |
| 2024-04-12 | Hooks Corwin Dale | Buy | 0 | |
| 2024-03-14 | Shendelman Shoshana | Sell | 318 573 | Common Stock |
| 2024-03-14 | Perfetti Riccardo | Sell | 110 804 | Common Stock |
| 2024-03-14 | Hansard Adam | Sell | 48 871 | Common Stock |
| INSIDER POWER |
|---|
| 41.60 |
| Last 97 transactions |
| Buy: 24 985 894 | Sell: 4 549 161 |
Forecast:
16:00 - $4.28
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.28
Forecast 2: 16:00 - $4.28
Forecast 3: 16:00 - $4.28
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.28 (1.18% ) |
| Volume | 0.429 mill |
| Avg. Vol. | 1.810 mill |
| % of Avg. Vol | 23.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APLT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.71 | N/A | Active |
|---|
APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Applied Therapeutics Appoints Dale Hooks As Chief Commercial Officer
New york, april 15, 2024 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the appointment of dale hooks as chief commercial officer, replacing adam hansard, effective immediately. mr. hooks joins applied with over 30 years of biopharmaceutical experience in rare disease marketing and sales, holding various leadership roles. mr. hooks will be responsible for leading applied's commercial preparations for the potential launch of govorestat for the treatment of classic galactosemia and sord.
2024-03-28 16:30:00 - Press Release
Applied Therapeutics Provides Fda Update On Pdufa Target Action Date For Govorestat For The Treatment Of Classic Galactosemia
New york, march 28, 2024 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the u.s. food and drug administration (fda) has extended the review period for the new drug application (nda) for govorestat (at-007) for the treatment of classic galactosemia by three months. the fda has set a new prescription drug user fee act (pdufa) target action date of november 28, 2024.
2024-03-06 07:00:00 - Press Release
Applied Therapeutics Reports Fourth Quarter And Year-end 2023 Financial Results
New york, march 06, 2024 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt) (the “company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the fourth quarter and full year ended december 31, 2023.
2024-02-28 08:05:00 - Press Release
Applied Therapeutics Announces $100 Million Private Placement
Financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors
2024-02-28 08:00:00 - Press Release
Applied Therapeutics Announces Fda Acceptance And Priority Review Of New Drug Application For Govorestat For The Treatment Of Classic Galactosemia
Pdufa target action date of august 28, 2024 maa validated and accepted for review by ema in december 2023 new york, feb. 28, 2024 (globe newswire) -- applied therapeutics, inc. (nasdaq: aplt), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the u.s. food and drug administration (fda) has accepted the filing of the new drug application (nda) for govorestat (at-007) for the treatment of classic galactosemia. the nda was granted priority review status, and the fda assigned a prescription drug user free act (pdufa) target action date of august 28, 2024.
Latest News
2024-03-28 16:52:59 - Reuters
US FDA extends review of Applied Therapeutics' genetic disease drug
The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday.
2024-03-13 10:26:16 - Zacks Investment Research
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.
2024-02-28 09:48:06 - InvestorPlace
Why Is Applied Therapeutics (APLT) Stock Up 59% Today?
Applied Therapeutics (NASDAQ: APLT ) stock is on the rise Wednesday after the clinical-stage biopharmaceutical company got an update from the Food and Drug Administration (FDA). The FDA has accepted the company's New Drug Application (NDA) for govorestat as a treatment for Classic Galactosemia.
2024-02-16 15:25:00 - Seeking Alpha
Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
Positive 12-month interim results from the phase 3 INSPIRE study using govorestat for the treatment of patients with SORD deficiency achieved. Pre-NDA meeting with FDA to be sought out after to see if an NDA submission of govorestat for SORD deficiency could be done with only the positive 12-month interim data. 24-month interim results from the phase 3 INSPIRE study, using govorestat for the treatment of patients with SORD deficiency, is the next data readout to be expected.
2024-01-05 11:29:52 - Proactive Investors
Applied Therapeutics stock falters on heart disease trial failure
Applied Therapeutics shares plunged almost 35% after the biotechnology firm reported disappointing results from its Phase 3 heart disease trial. The company reported that its ARISE-HF trial of drug candidate AT-001 (caficrestat) in patients with diabetic cardiomyopathy (DbCM) at high risk of progressing to overt heart failure did not meet its primary endpoint of stabilization or improvement in cardiac functional capacity as measured by peak VO2.
2024-01-05 09:23:48 - InvestorPlace
Why Is Applied Therapeutics (APLT) Stock Down 30% Today?
Applied Therapeutics (NASDAQ: APLT ) stock is falling on Friday following the release of Phase 3 clinical trial data from the clinical-stage biopharmaceutical company. This data comes from Applied Therapeutics' ARISE-HF Phase 3 trial of AT-001 in patients with Diabetic Cardiomyopathy who have a high risk of overt heart failure.
2023-12-07 15:36:49 - PennyStocks
3 Penny Stocks To Buy According To Insiders In December
Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.
2023-09-28 07:00:00 - GlobeNewsWire
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting
The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in patients with diabetic cardiomyopathy (DbCM) Baseline data from ARISE-HF shows patients with DbCM exhibit reduced cardiac functional capacity resulting in decreased physical activity NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will participate in a Symposium presentation, entitled Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes, at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting to take place October 2-6, 2023 in Hamburg, Germany and online.
2023-08-17 04:28:21 - Seeking Alpha
Applied Therapeutics: Buy For Upcoming Pre-NDA Meeting (I Expect A Positive Outcome)
Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in diabetic cardiomyopathy) and a huge upside potential. Despite missing the primary endpoint in galactosemia ph3 trial, APLT still plans for NDA submission. The pre-NDA meeting with the FDA this summer will be a big catalyst if positive. I expect a positive outcome from the meeting considering consistent and meaningful clinical benefit in multiple endpoints, orphan and fast-track designation, no alternative treatments, and the significant burden for affected patients.
2023-06-22 07:00:00 - GlobeNewsWire
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple presentations on AT-001 (caficrestat) and the ARISE-HF Phase 3 study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association to take place June 23 - 26 in San Diego, California.